Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer
Anthony V D'Amico, Ming-Hui Chen, Juanita Crook, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 4, 2011
Another form of subgroup to beware
James W Denham, David S Lamb, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 16, 2003
The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck
Tiffany Daly, Michael G Poulsen, James W Denham, et al.
Cancer
|
August 20, 2009
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
James W Denham, Allison Steigler, Chantelle Wilcox, et al.
Pathology
|
May 5, 2010
Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point
Brett Delahunt, David S Lamb, John R Srigley, et al.
Journal of Medical Imaging and Radiation Oncology
|
August 2, 2014
Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
Martin A Ebert, Max Bulsara, Annette Haworth, et al.
Anticancer Research
|
December 1, 2017
Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure
David S Lamb, Sven Sondhauss, Jonathan C Dunne, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2010
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial
David S Lamb, James W Denham, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 18, 2008
Thrombin generation as a predictor of radiotherapy induced skin erythema
Lisa F Lincz, Sanjiv A Gupta, Christopher R Wratten, et al.
Journal of Medical Imaging and Radiation Oncology
|
April 5, 2013
Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial
Rachel Kearvell, Annette Haworth, Martin A Ebert, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer
Anthony V D'Amico, Ming-Hui Chen, Juanita Crook, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
October 4, 2011
Another form of subgroup to beware
James W Denham, David S Lamb, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 16, 2003
The effect of anaemia on efficacy and normal tissue toxicity following radiotherapy for locally advanced squamous cell carcinoma of the head and neck
Tiffany Daly, Michael G Poulsen, James W Denham, et al.
Cancer
|
August 20, 2009
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
James W Denham, Allison Steigler, Chantelle Wilcox, et al.
Pathology
|
May 5, 2010
Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point
Brett Delahunt, David S Lamb, John R Srigley, et al.
Journal of Medical Imaging and Radiation Oncology
|
August 2, 2014
Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
Martin A Ebert, Max Bulsara, Annette Haworth, et al.
Anticancer Research
|
December 1, 2017
Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure
David S Lamb, Sven Sondhauss, Jonathan C Dunne, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2010
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial
David S Lamb, James W Denham, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 18, 2008
Thrombin generation as a predictor of radiotherapy induced skin erythema
Lisa F Lincz, Sanjiv A Gupta, Christopher R Wratten, et al.
Journal of Medical Imaging and Radiation Oncology
|
April 5, 2013
Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial
Rachel Kearvell, Annette Haworth, Martin A Ebert, et al.
Page
of 10